The news is directly about Viridian Therapeutics. While the Outperform rating is maintained, the lowering of the price target could indicate a potential slowdown in the company's growth or a reassessment of its value. This could have a neutral impact on the stock price in the short term as the positive and negative aspects of the news may balance each other out.